Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
P/E Ratio
--
P/B Ratio
2.11
Industry P/E
--
Debt to Equity
0.08
ROE
-1.36 %
ROCE
-131.48 %
Div. Yield
0 %
Book Value
1.99
EPS
-7.25
CFO
$-129.68 Mln
EBITDA
$-163.86 Mln
Net Profit
$-120.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
| -34.71 | 1.83 | -36.93 | -75.87 | -65.61 | -59.34 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
| -86.58 | -19.02 | -43.01 | -61.11 | -12.89 | -12.01 | -43.91 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 62.74 | 11,346.08 | 26.54 | 8.05 | |
| 71.79 | 6,636.14 | 51.14 | 23.56 | |
| 58.97 | 11,265.03 | 378.67 | 0.76 | |
| 8.03 | 9,036.23 | -- | -3.24 |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of... relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. Address: 5300 Memorial Drive, Houston, TX, United States, 77007 Read more
Founder, Chairman, President & CEO
Mr. Walter V. Klemp
Founder, Chairman, President & CEO
Mr. Walter V. Klemp
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Moleculin Biotech Inc (MBRX) stood at $ 17 Mln as on 31-Dec-24
The share price of Moleculin Biotech Inc (MBRX) is $1.11 (NASDAQ) as of 24-Apr-2025 16:07 EDT. Moleculin Biotech Inc (MBRX) has given a return of -65.61% in the last 3 years.
Moleculin Biotech Inc (MBRX) has a market capitalisation of $ 13 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Moleculin Biotech Inc (MBRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Moleculin Biotech Inc (MBRX) and enter the required number of quantities and click on buy to purchase the shares of Moleculin Biotech Inc (MBRX).
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. Address: 5300 Memorial Drive, Houston, TX, United States, 77007
The CEO & director of Mr. Walter V. Klemp. is Moleculin Biotech Inc (MBRX), and CFO & Sr. VP is Mr. Walter V. Klemp.
There is no promoter pledging in Moleculin Biotech Inc (MBRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Moleculin Biotech Inc. (MBRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-135.8
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Moleculin Biotech Inc (MBRX) was $0 Mln.
$0.08
(
